Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | February 01, 2018 | February 05, 2018 |
| Medpace Holdings, Inc.MEDP · Entity 3327 | Director · President & CEO · 10% owner | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 20,000 |
Reported balance
After 2018-02-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-01 · Grant · Acquired 20,000 · Balance 20,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 29,994 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,994 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 1,642,492 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,642,492 F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 268,428 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 268,428 F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.
F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Medpace Holdings, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 338,225 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Sale · Disposed 26,701 · Balance 360,191 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Row 2 · 2026-09-30 · Sale · Disposed 21,966 · Balance 338,225 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Medpace Investors, LLC | 4,733,019 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,733,019 F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2019 Filed Feb 5, 2019 21:28 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 84,093 | $65.54 | $5,511,455.22 |
DisclosureSEC source: 0001567619-19-002372 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,770,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $63.61 to $66.775. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 31, 2019 Filed Jan 31, 2019 21:54 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 68,383 | $64.19 | $4,389,504.77 |
DisclosureSEC source: 0001567619-19-002038 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,854,138 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $63.32 to $64.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 21:54 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 102,828 | $63.22 | $6,500,786.16 |
DisclosureSEC source: 0001567619-19-002038 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 7,922,521 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $64.43. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 21:54 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 1,100 | $61.05 | $67,155.00 |
DisclosureSEC source: 0001567619-19-002038 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,025,349 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.18. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 28, 2019 Filed Jan 28, 2019 21:59 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 4,221 | $61.04 | $257,649.84 |
DisclosureSEC source: 0001567619-19-001785 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,026,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.19. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 21:59 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 27,958 | $61.13 | $1,709,072.54 |
DisclosureSEC source: 0001567619-19-001785 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,030,670 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 21:59 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,501 | $61.14 | $214,051.14 |
DisclosureSEC source: 0001567619-19-001785 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,058,628 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 23, 2019 Filed Jan 23, 2019 21:50 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 24,160 | $61.22 | $1,479,075.20 |
DisclosureSEC source: 0001567619-19-001507 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,062,129 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.79. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 21:50 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 9,936 | $61.10 | $607,089.60 |
DisclosureSEC source: 0001567619-19-001507 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,086,289 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.31. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:50 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 38,318 | $61.43 | $2,353,874.74 |
DisclosureSEC source: 0001567619-19-001507 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,096,225 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 17, 2019 Filed Jan 17, 2019 21:42 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,760 | $61.17 | $535,849.20 |
DisclosureSEC source: 0001567619-19-001305 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,134,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 17, 2019 Filed Jan 23, 2019 21:52 UTC Amendment | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 8,760 | $61.17 | $535,849.20 |
DisclosureSEC source: 0001567619-19-001509 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,134,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · kind: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · shares: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F4 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 21:42 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,222 | $61.57 | $444,658.54 |
DisclosureSEC source: 0001567619-19-001305 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,143,303 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $62.07. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 16, 2019 Filed Jan 23, 2019 21:52 UTC Amendment | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 7,222 | $61.57 | $444,658.54 |
DisclosureSEC source: 0001567619-19-001509 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,143,303 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · kind: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · shares: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $62.07. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F4 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:42 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 600 | $61.00 | $36,600.00 |
DisclosureSEC source: 0001567619-19-001305 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,150,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.01. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 15, 2019 Filed Jan 23, 2019 21:52 UTC Amendment | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 600 | $61.00 | $36,600.00 |
DisclosureSEC source: 0001567619-19-001509 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,150,525 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · kind: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 15, 2018. F2 · shares: Amendment to Form 4 filing dated January 17, 2019 to report MPI as the correct party to adopt the Rule 10b5-1 trading plan. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $61.00 to $61.01. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F4 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:38 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 251,851 | $59.91 | $15,088,393.41 |
DisclosureSEC source: 0001567619-18-003362 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,702 F3 · kind: Represents the receipt of the allocable portion of shares in the distribution by MPI as more fully described in Footnote 1. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:38 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 748,459 | $59.91 | $44,840,178.69 |
DisclosureSEC source: 0001567619-18-003362 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,147,051 F1 · kind: Represents distributions of MEDP shares in-kind to the holders of Medpace Investors, LLC's ("MPI") Incentive Units. F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:55 UTC Amendment | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 747,454 | $59.91 | $44,779,969.14 |
DisclosureSEC source: 0001567619-18-003531 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,148,056 F1 · kind: Represents distributions of MEDP shares in-kind to the holders of Medpace Investors, LLC's ("MPI") Incentive Units. F2 · shares: Amendment to Form 4 filing dated October 1, 2018 to report adjusted amount of shares distributed. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 28, 2018 Filed Oct 11, 2018 20:35 UTC Amendment | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 744,385 | $59.91 | $44,596,105.35 |
DisclosureSEC source: 0001567619-18-003994 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,151,125 F1 · kind: Represents distributions of MEDP shares in-kind to the holders of Medpace Investors, LLC's ("MPI") Incentive Units. F2 · shares: Second amendment to Form 4 filing dated October 1, 2018 to report adjusted amount of shares distributed. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 27, 2018 Filed Sep 27, 2018 20:56 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 46,778 | $58.96 | $2,758,030.88 |
DisclosureSEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,895,510 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $59.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 20:56 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 46,886 | $58.38 | $2,737,204.68 |
DisclosureSEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,942,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $59.29. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:56 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 38,640 | $58.36 | $2,255,030.40 |
DisclosureSEC source: 0001567619-18-003214 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 8,989,174 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:36 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 2,713 | $58.47 | $158,629.11 |
DisclosureSEC source: 0001567619-18-003049 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 9,027,814 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.22 to $58.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:05 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 53,842 | $58.29 | $3,138,450.18 |
DisclosureSEC source: 0000899243-18-025027 · doc4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 9,030,527 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.74. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 22:05 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 61,141 | $60.20 | $3,680,688.20 |
DisclosureSEC source: 0000899243-18-025027 · doc4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 9,084,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on August 20, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $64.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:55 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 138,105 | $57.06 | $7,880,271.30 |
DisclosureSEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,851 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.96 to $58.16. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 06, 2018 Filed Aug 6, 2018 23:32 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 156,369 | $58.51 | $9,149,150.19 |
DisclosureSEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,956 F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.84 to $59.59. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 23:32 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 203,296 | $59.94 | $12,185,562.24 |
DisclosureSEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,325 F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F3 · price: The reported full price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.87 to $61.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 23:32 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 371,795 | $59.20 | $22,010,264.00 |
DisclosureSEC source: 0000899243-18-021486 · doc4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,621 F1 · kind: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F1 · shares: The sales reported in this Form 4 were effected Pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.81 to $60.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002890 · doc4.xml · derivative · entry 4 Troendle August J. · CIK 0001622058 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| July 31, 2017 Filed Aug 9, 2018 20:55 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 37,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 9,145,510 F3 · kind: Issuer shares were disposed of by MPI through an in-kind exchange of Class B units of MPI acquired by an individual. F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2017 Filed Aug 9, 2018 20:55 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | OtherCommon Stock | 27,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-000253 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 9,182,547 F1 · kind: Issuer shares were disposed of by Medpace Investors, LLC ("MPI) through an in-kind exchange of incentive units of MPI acquired by employees of entities affiliated with the Issuer. F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.80 | $0.00 |
DisclosureSEC source: 0000899243-17-013892 · doc4.xml · derivative · entry 4 Troendle August J. · CIK 0001622058 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-17 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.